High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.

"Conflict of interest statement: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Massimo Corradi has during the last 3 years received honoraria for lectures from Chiesi Farmaceutici, Italy. Piotr Kuna has during the last 3 years received honoraria for participating in advisory board meetings or giving lectures for the following companies: Adamed, Allergopharma, Almirall, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Celon Pharma, Chiesi, FAES, GSK, HAL, Meda, MSD, Novartis, Pfizer, Polpharmex, Polpharma, Stallergen, Teva. Monica Spinola and Stefano Petruzzelli are full time Chiesi Farmaceutici employees."

"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Chiesi Farmaceutici, Parma, Italy."